News

Securities Litigation Exposure for Life Science Companies

May 30, 2019
Arnold & Porter Webinar

Securities litigation exposure for life sciences companies is on the rise with approximately 1 out of every 5 securities fraud class actions suits being brought against a life sciences company.

During this webinar, our attorneys take an in-depth look at the recent cases impacting this trend, the pitfalls many life sciences companies face in both product development and marketing, and how to mitigate the common legal issues in defending securities class actions.

Webinar Series Information

Counsel and compliance professionals at life sciences companies must be prepared to identify, assess and mitigate the potential risks to their businesses stemming from surging whistleblower activity and aggressive governmental investigations and private securities litigation.

Securities Enforcement and Disputes in the Life Sciences Industry is a five-part webinar series led by a team of Arnold & Porter attorneys comprised of former SEC, DOJ, and other seasoned litigators with decades of experience handling life sciences-related securities enforcement and disputes. The series is designed for life sciences company counsel and compliance professionals at all levels, equipping attendees with the tools needed to manage critical issues that arise in securities enforcement and litigation. Each webinar is self-contained and stands alone; those interested can attend one, some, or all sessions as they like. Detailed information on the forthcoming webinars is linked below.

Wednesday, June 19, 2019
» Tired of Securities Enforcement Actions Targeting the Life Sciences Industry?

Wednesday, September 18, 2019
» The Perfect Storm: Handling Concurrent Governmental Investigations, Internal Investigations and Private Securities Litigation

Wednesday, October 16, 2019
» M&A Litigation and Commercial Disputes

Wednesday, November 13, 2019
» Ethics Considerations When Interacting With Current and Former Employees During Investigations and Litigation

Email Disclaimer